[24 hour warning] These 7 stocks are reporting earnings very soon

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [New "Alternative" Currency Make Biden's Plans Obsolete?]( [If you’re worried about Biden’s “Digital Dollar” then you must check out this new “alternative” currency immediately…Click here now for all of the details.]( --------------------------------------------------------------- November 17, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia]( The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." [Early investors can reap 5,633% gains on the small company revolutionizing warfare ]( --------------------------------------------------------------- [Korro Bio]( Symbol: [KRRO]( Recent Price: $40.80 Average Analyst Price Target: $90.25 (121.20%) Market Cap: $334.85M Last Year's EPS: -$15.5 Consensus EPS Forecast: -$17.73 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Yasmeen Rahimi, analyst at Piper Sandler, reiterates coverage on [Korro Bio (KRRO)]( in the Healthcare sector with a Buy rating and a price target of $180 (6 days ago). [TipRanks.com]( also reports that [Korro Bio]( currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $90.25 . The target pricing ranges from a high forecast of $180 down to a low forecast of $0.5. [Korro Bio (KRRO)](’s last closing price was $40.80 which would put the average price target at 121.20% upside. Here are 3rd party ratings for [KRRO](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 22% (56 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Tech Insider: "ChatGPT's IPO - is this the final clue?"]( posted a strange legal promise to early investors on their website -- And what it says is truly shocking if you read between the lines. It’s why venture capitalist Luke Lango now believes an IPO announcement could happen at any moment. [Click here to see how to prepare.]( --------------------------------------------------------------- [Enanta Pharmaceuticals]( Symbol: [ENTA]( Recent Price: $8.69 Average Analyst Price Target: $19.60 (126.35%) Market Cap: $186.76M Last Year's EPS: -$1.79 Consensus EPS Forecast: -$2.38 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Ed Arce, analyst at H.C. Wainwright, reiterates coverage on [Enanta Pharmaceuticals (ENTA)]( in the Healthcare sector with a Buy rating and a price target of $30 (3 weeks ago). [TipRanks.com]( also reports that [Enanta Pharmaceuticals]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.60 . The target pricing ranges from a high forecast of $30 down to a low forecast of $14. [Enanta Pharmaceuticals (ENTA)](’s last closing price was $8.69 which would put the average price target at 126.35% upside. Here are 3rd party ratings for [ENTA](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Strong Sell, Top 30% (74 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Bioline RX Ltd Sponsored ADR]( Symbol: [BLRX]( Recent Price: $1.86 Average Analyst Price Target: $12.50 (1,029.03%) Market Cap: $104.72M Last Year's EPS: -$0.15 Consensus EPS Forecast: -$0.16 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Bioline RX Ltd Sponsored ADR (BLRX)]( in the Healthcare sector with a Buy rating and a price target of $21 (1 month ago). [TipRanks.com]( also reports that [Bioline RX Ltd Sponsored ADR]( currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $12.50 . The target pricing ranges from a high forecast of $4 down to a low forecast of $21. [Bioline RX Ltd Sponsored ADR (BLRX)](’s last closing price was $1.86 which would put the average price target at 1,029.03% upside. Here are 3rd party ratings for [BLRX](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [AI to Disrupt Energy Market (Huge Potential Gains!)]( orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… It makes them all look like small fries… In fact, just one year of this untapped resource in the USA alone provides 5X as much power as the largest oil field on Earth… And this resource is about to be unleashed on the world like never before with the help of one tiny Silicon Valley company…[Click here for all the details…]( --------------------------------------------------------------- [Enlivex]( Symbol: [ENLV]( Recent Price: $1.74 Average Analyst Price Target: $12.00 (589.66%) Market Cap: $31.79M Last Year's EPS: -$0.39 Consensus EPS Forecast: -$0.43 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Enlivex (ENLV)]( in the Healthcare sector with a Buy rating and a price target of $12 (3 days ago). [TipRanks.com]( also reports that [Enlivex]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $12.00 . The target pricing ranges from a high forecast of $12 down to a low forecast of $12. [Enlivex (ENLV)](’s last closing price was $1.74 which would put the average price target at 589.66% upside. Here are 3rd party ratings for [ENLV](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Buy, Top 30% (74 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [BM Technologies]( Symbol: [BMTX]( Recent Price: $2.38 Average Analyst Price Target: $8.42 (157.56%) Market Cap: $28.49M Last Year's EPS: -$0.43 Consensus EPS Forecast: -$0.32 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Michael Diana, analyst at Maxim Group, reiterates coverage on [BM Technologies (BMTX)]( in the Technology sector with a Buy rating and a price target of $8 (2 months ago). [TipRanks.com]( also reports that [BM Technologies]( currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.42 . The target pricing ranges from a high forecast of $8 down to a low forecast of $13. [BM Technologies (BMTX)](’s last closing price was $2.38 which would put the average price target at 157.56% upside. Here are 3rd party ratings for [BMTX](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 45% (137 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Buffet and Pelosi Betting Millions on Apple Project?]( ��s next device lies at the center of an industry projected to grow 19,254%... and a tiny $5 stock is poised to soar 40X once it goes live. --------------------------------------------------------------- [ReNew Energy Global]( Symbol: [RNW]( Recent Price: $5.90 Average Analyst Price Target: $8.25 (48.81%) Market Cap: $2.24B Last Year's EPS: $0.19 Consensus EPS Forecast: $0.09 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Puneet Gulati, analyst at HSBC, reiterates coverage on [ReNew Energy Global (RNW)]( in the Utilities sector with a Buy rating and a price target of $8.75 (1 month ago). [TipRanks.com]( also reports that [ReNew Energy Global]( currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.25 . The target pricing ranges from a high forecast of $9 down to a low forecast of $7. [ReNew Energy Global (RNW)](’s last closing price was $5.90 which would put the average price target at 48.81% upside. Here are 3rd party ratings for [RNW](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 26% (64 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Agilent]( Symbol: [A]( Recent Price: $114.19 Average Analyst Price Target: $132.50 (4.80%) Market Cap: $32.66B Last Year's EPS: $1.27 Consensus EPS Forecast: $1.37 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Neil Beveridge, analyst at Bernstein, reiterates coverage on [Agilent (A)]( in the Healthcare sector with a Sell rating (1 week ago). [TipRanks.com]( also reports that [Agilent]( currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $132.50 . The target pricing ranges from a high forecast of $150 down to a low forecast of $105. [Agilent (A)](’s last closing price was $114.19 which would put the average price target at 4.80% upside. Here are 3rd party ratings for [A](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 35% (88 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [AI Stock Caught Trading Under Secret Name]( Some friends of mine just put out a new webinar, all about 0DTE options. And I just got access to the recordings! If you’re not familiar with these short term fast trade options… Now’s your chance to learn all about 0DTE options. The webinar is called [“Quickfire 0DTE Options Trade Generator: Fast Trades, Faster Results”.]( The webinar is less than an hour, but it’s packed with knowledge for options traders! [Here’s the recording of the webinar…]( [Watch it now](- because they said they’re going to take it offline on Friday. --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, InsideTraderAlerts.com InsideTraderAlerts Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( InsideTraderAlerts part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software